These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 19127428)

  • 1. Haplotypes of XRCC1 and survival outcome in patients with metastatic breast cancer.
    Bewick MA; Conlon MS; Lafrenie RM
    Breast Cancer Res Treat; 2009 Oct; 117(3):667-9. PubMed ID: 19127428
    [No Abstract]   [Full Text] [Related]  

  • 2. Polymorphisms in XRCC1, XRCC3, and CCND1 and survival after treatment for metastatic breast cancer.
    Bewick MA; Conlon MS; Lafrenie RM
    J Clin Oncol; 2006 Dec; 24(36):5645-51. PubMed ID: 17116943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
    Sun X; Li F; Sun N; Shukui Q; Baoan C; Jifeng F; Lu C; Zuhong L; Hongyan C; YuanDong C; Jiazhong J; Yingfeng Z
    Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. XRCC1 Arg399Gln and RAD51 5'UTR G135C polymorphisms and their outcome in tumor aggressiveness and survival of Portuguese breast cancer patients.
    Costa S; Pinto D; Pereira D; Rodrigues H; Cameselle-Teijeiro J; Medeiros R; Schmitt F
    Breast Cancer Res Treat; 2008 May; 109(1):183-5. PubMed ID: 17616806
    [No Abstract]   [Full Text] [Related]  

  • 5. Test may help predict chemotherapy response and survival in breast cancer.
    Printz C
    Cancer; 2011 Oct; 117(19):4339. PubMed ID: 21928334
    [No Abstract]   [Full Text] [Related]  

  • 6. Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer.
    Schrama JG; Rodenhuis S; de Gast GC
    Bone Marrow Transplant; 2003 Jan; 31(2):141-2. PubMed ID: 12621498
    [No Abstract]   [Full Text] [Related]  

  • 7. Overcoming drug resistance in patients with metastatic breast cancer.
    Wong ST; Goodin S
    Pharmacotherapy; 2009 Aug; 29(8):954-65. PubMed ID: 19637949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival impact of integrative cancer care in advanced metastatic breast cancer.
    Block KI; Gyllenhaal C; Tripathy D; Freels S; Mead MN; Block PB; Steinmann WC; Newman RA; Shoham J
    Breast J; 2009; 15(4):357-66. PubMed ID: 19470134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy.
    Huang ZH; Hua D; Du X
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):1001-7. PubMed ID: 19247656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered expression of proliferation-inducing and proliferation-inhibiting genes might contribute to acquired doxorubicin resistance in breast cancer cells.
    Saleh EM; El-Awady RA; Abdel Alim MA; Abdel Wahab AH
    Cell Biochem Biophys; 2009; 55(2):95-105. PubMed ID: 19593673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA repair gene XRCC1 polymorphisms and haplotypes in diffuse large B-cell lymphoma in a Korean population.
    Kim IS; Kim DC; Kim HG; Eom HS; Kong SY; Shin HJ; Hwang SH; Lee EY; Kim S; Lee GW
    Cancer Genet Cytogenet; 2010 Jan; 196(1):31-7. PubMed ID: 19963133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-nucleotide polymorphisms of DNA repair genes OGG1 and XRCC1: association with gallbladder cancer in North Indian population.
    Srivastava A; Srivastava K; Pandey SN; Choudhuri G; Mittal B
    Ann Surg Oncol; 2009 Jun; 16(6):1695-703. PubMed ID: 19266243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.
    Tanei T; Morimoto K; Shimazu K; Kim SJ; Tanji Y; Taguchi T; Tamaki Y; Noguchi S
    Clin Cancer Res; 2009 Jun; 15(12):4234-41. PubMed ID: 19509181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Introduction: chemotherapies in the treatment of breast cancer.
    Fojo AT
    Semin Oncol; 2005 Dec; 32(6 Suppl 7):S1-2. PubMed ID: 16360715
    [No Abstract]   [Full Text] [Related]  

  • 15. From improved survival to potential cure in patients with metastatic breast cancer.
    Kobayashi T
    Breast Cancer; 2012 Jul; 19(3):187-90. PubMed ID: 22328289
    [No Abstract]   [Full Text] [Related]  

  • 16. Polymorphisms of DNA base-excision repair genes APE/Ref-1 and XRCC1 are not associated with the risk for Graves' disease.
    Doğru-Abbasoğlu S; Tanrikulu S; Ademoğlu E; Erbil Y; Ozderya A; Karadağ B; Uysal M
    Cell Biochem Funct; 2009 Oct; 27(7):462-7. PubMed ID: 19711438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence to quality indicators and survival in patients with breast cancer.
    Cheng SH; Wang CJ; Lin JL; Horng CF; Lu MC; Asch SM; Hilborne LH; Liu MC; Chen CM; Huang AT
    Med Care; 2009 Feb; 47(2):217-25. PubMed ID: 19169123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphism of the homologous recombination repair genes RAD51 and XRCC3 in breast cancer.
    Krupa R; Synowiec E; Pawlowska E; Morawiec Z; Sobczuk A; Zadrozny M; Wozniak K; Blasiak J
    Exp Mol Pathol; 2009 Aug; 87(1):32-5. PubMed ID: 19426727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between XRCC1 polymorphisms and head and neck cancer in a Hungarian population.
    Csejtei A; Tibold A; Koltai K; Varga Z; Szanyi I; Gobel G; Prantner I; Steffler D; Feher G; De Blasio A; Ember I; Kiss I
    Anticancer Res; 2009 Oct; 29(10):4169-73. PubMed ID: 19846968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy in advanced breast cancer should be evaluated by time to progression].
    Song ST
    Zhonghua Yi Xue Za Zhi; 2007 Jan; 87(2):73-5. PubMed ID: 17418008
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.